LAKE:NASDAQLakeland Industries, Inc. Analysis
Data as of 2026-04-14 - not real-time
Latest Price
Risk Level: High
Executive Summary
Lakeland Industries (LAKE) is trading at $9.07, just below the calculated resistance of $9.35 and above the 20‑day SMA of $8.36, while the 20‑day SMA remains beneath the 50‑day SMA of $8.94, signaling a short‑term bearish bias. The RSI sits at 58.6, indicating modest momentum, and the MACD histogram is positive (0.158) despite a modestly bullish signal line, suggesting limited upside momentum. Volatility is elevated at 45% over the past 30 days and beta is 1.10, reflecting higher-than‑market price swings, and volume trends are decreasing, raising liquidity concerns. A class‑action securities‑fraud lawsuit filed in March 2026 adds a significant regulatory headwind that could pressure the stock further. Fundamentally, the company reports negative gross (34.8%) and operating margins, a trailing EPS of –$4.48, and negative cash flows, yet it carries a forward EPS of $0.21 and a forward P/E of 43.2, implying a high valuation relative to expected earnings. The price‑to‑book ratio of 0.66 and price‑to‑sales of 0.46 suggest the stock is cheap on a balance‑sheet basis, but the dividend yield of 0.8% is likely unsustainable given the earnings and cash‑flow deficits. Analysts’ consensus remains a “buy” with a median target of $15, but the confluence of technical weakness, legal risk, and weak fundamentals makes the near‑term outlook precarious.
Market Outlook
Short Term
< 1 yearKey Factors
- Bearish SMA crossover and price near resistance
- Elevated volatility and decreasing volume
- Ongoing securities‑fraud litigation
Medium Term
1–3 yearsKey Factors
- Negative margins and cash‑flow deficits
- Potential upside from low price‑to‑book valuation
- Uncertainty around legal resolution
Long Term
> 3 yearsKey Factors
- Forward EPS positivity and analyst price targets
- Undervalued balance‑sheet metrics (P/B, P/S)
- Possibility of operational turnaround if litigation settles
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.